Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVI-4065 in Chronic Active Hepatitis C
NCT00229749Phase 2Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2005
- Primary completion
- Oct 2006
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
A Phase 2 trial of AVI-4065 in hepatitis C virus infection, sponsored by Sarepta Therapeutics. Started Sep 2005; status: terminated.
02
Drugs
AVI-4065
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00229749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229749.